Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi, miRNA and Epigenetics

David Shum's Biography

David Shum, Assay Development Specialist, Memorial Sloan-Kettering Cancer Center

David Shum has over seven years of extensive drug discovery experience in assay development and screening. He joined the HTS Core in 2004 and has been at the forefront of developing high-content and biochemical assays for screening across therapeutic target areas in oncology, antivirals such as HIV and Dengue. To date, he has successfully performed over 20 screens for both chemical and RNAi libraries leading to the identification of several hits; one of which a CDC7 kinase inhibitor being currently developed for treating refractory cancers. David received his M.Sc. in Biology from New York University in 2002 and has been at Memorial Sloan-Kettering Cancer Center since 2002.

David Shum Image

Discovery and Characterization of a Novel Regulatory Gene of the miRNA Biogenesis Pathway: Implications in Cancer Drug Discovery

Wednesday, 14 November 2012 at 11:45

Add to Calendar ▼2012-11-14 14:45:002012-11-14 15:45:00Europe/LondonTitle to be

miRNA dysregulation are associated with many disease states and genes/pathways to modulating their biogenesis are highly sought after. I will present the discovery of several regulatory genes involved in the miRNA biogenesis and discuss their significance as potential druggable targets in cancer therapy.

Add to Calendar ▼2012-11-13 00:00:002012-11-14 00:00:00Europe/LondonRNAi, miRNA and